Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors

Lignende værker

• SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
  af: El Mouhayyar, Christopher, et al.
  Udgivet: (2020)
• The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
  af: Schernthaner, Guntram, et al.
  Udgivet: (2014)
• COMBINATION THERAPY WITH GLP-1 RECEPTOR AGONIST AND SGLT2 INHIBITOR
  af: DeFronzo, Ralph A.
  Udgivet: (2017)
• The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
  af: de Wit, Helena M., et al.
  Udgivet: (2016)
• Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
  af: Røder, Michael E.
  Udgivet: (2017)